Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35
Anticancer Research · 2023
DOI: 10.21873/anticanres.16190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Ryosuke Ono und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Oncolytic adenoviruses (Ads) (OAds) are gaining attention as an effective remedy for pancreatic cancer. Most OAds are based on human Ad serotype 5 (Ad5) (OAd5); however, two major drawbacks of OAd5 have been reported. Expression of coxsackievirus-adenovirus receptor, a primary infection receptor of Ad5, is often decreased on malignant tumor cells, including pancreatic cancers. More than 60% of adults have neutralizing antibodies against Ad5. Previously, we developed an OAd composed of Ad serotype 35 (Ad35) (OAd35). Ad35 recognizes CD46, which is often up-regulated on pancreatic cancers. In addition, only 20% or fewer adults have anti-Ad35 neutralizing antibodies. MATERIALS AND METHODS: We examined the tumor cell lysis activities of OAd35 in the four human pancreatic cancer cell lines in the presence and absence of human serum. The tumor growth suppression effects of OAd35 after local and systemic administration were evaluated in nude mice bearing human pancreatic tumors. RESULTS: OAd35 showed higher levels of tumor cell lysis activities than OAd5 in the human pancreatic cancer cell lines AsPC-1 and BxPC-3. Although the in vitro tumor cell lysis activities of OAd5 against MIA PaCa-2 and PANC-1 cells were strongly attenuated in the presence of human serum, OAd35 mediated comparable levels of tumor cell lysis in the presence and absence of human serum. Systemic administration of OAd5 did not mediate significant growth inhibition against the subcutaneous BxPC-3 tumor. On the other hand, OAd35 significantly suppressed tumor growth. CONCLUSION: OAd35 would be suitable as an alternative anticancer agent for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
- Laboratory of Biochemistry and Molecular Biology, School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
- Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; sakurai@phs.osaka-u.ac.jp.
- Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; mizuguch@phs.osaka-u.ac.jp.
- Laboratory of Functional Organoid for Drug Discovery, Center for Drug Discovery Resources Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
- Global Center for Medical Engineering and Informatics, Osaka University, Osaka, Japan.
Zitieren
APA
Ono, R., Takayama, K., Onishi, R., Tokuoka, S., Sakurai, F., & Mizuguchi, H. (2023). Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35. Anticancer Research. https://doi.org/10.21873/anticanres.16190
Vancouver
Ono R, Takayama K, Onishi R, Tokuoka S, Sakurai F, Mizuguchi H. Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35. Anticancer Research. 2023. doi:10.21873/anticanres.16190
BibTeX
@article{Ono2023,
author = {Ono, Ryosuke and Takayama, Kosuke and Onishi, Rika and Tokuoka, Sora and Sakurai, Fuminori and Mizuguchi, Hiroyuki},
title = {Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16190}
}
EUVIMED